SCHEMBL6923028

SCHEMBL6923028

CC(C)Cc1nc2cc(-c3cccc(F)c3)ccc2c(=O)n1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 1/20 0.42
TNKS2 Q9H2K2 1/20 0.41
CYP3A4 P08684 3/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
TGFBR1 P36897 1/20 0.40
PDE10A Q9Y233 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39
BACE1 P56817 1/20 0.38
PGR P06401 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
LRRK2 Q5S007 1/20 0.38
ICMT O60725 1/20 0.37
BCL2A1 Q16548 1/20 0.37
KDM5B Q9UGL1 1/20 0.36
CTSD P07339 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059535 0.84 CYP3A4 (0.41) TNKS2CYP3A4USP2ALDH1A1CYP1A2
SCHEMBL12059534 0.84 PIM1 (0.44) TNKS2CYP3A4USP2ALDH1A1CYP1A2
SCHEMBL2043908 0.83 GRM5 (0.41) PARG
SCHEMBL6921853 0.82 CYP3A4 (0.45) TNKS2CYP3A4USP2ALDH1A1CYP1A2
SCHEMBL12059512 0.82 BCL2A1 (0.42) TNKS2CYP3A4USP2ALDH1A1CYP1A2
SCHEMBL6920609 0.81 ALDH1A1 (0.47) ALDH1A1
SCHEMBL12059499 0.81 TGFBR1 (0.42) TNKS2CYP3A4USP2ALDH1A1CYP1A2
SCHEMBL6922981 0.78 TNKS2 (0.40) TNKS2CYP3A4USP2ALDH1A1CYP1A2
SCHEMBL6923289 0.76 PARG (0.47) PARGUSP2ALDH1A1TSHRHDAC6
SCHEMBL12059005 0.73 ICMT (0.47) TNKS2ALDH1A1TGFBR1PGRHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 PARG 4483/4885TNKS2 3475/4885CYP3A4 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.